Last minute data strengthens the ability to analyze by cardiac flow analysis to help physicians accurately stratify heart patients and provide more personalized care

Last minute results presented and published today confirm that the
HeartFlow^® The FFRct badysis allows doctors to
identify which patients despite the symptoms suggestive of a coronary artery
cardiovascular diseases (CAD) have a low risk of adverse cardiovascular events and may
Safely avoid invasive testing up to one year. These results of the
The ADVANCE trial was presented as a last-minute trial during the
American College of Cardiology (ACC) 68^th Annual scientist
Session and published simultaneously in the Journal of the American
College of Cardiology (JACC): Cardiovascular Imaging.

In the ADVANCE study of more than 5,000 patients, clinicians used FFRct
values ​​of cardiac flow badysis to help determine the risk of
adverse cardiovascular events and decide on management plans. The vast
The majority of patients who had a negative HeartFlow badysis received
medical treatment and has not been tested or treated invasively. AT
less than one year, patients in this group had a significantly low (0.2%)
cardiovascular death or heart attack (myocardial infarction). In
comparison, the rate of cardiovascular death or heart attack was four
times higher in patients with positive cardiac flow badysis, many
which required invasive management. These results demonstrate that
patients identified as having a lower risk of adverse events can do so safely
treated with drugs alone and avoid invasive management.
Importantly, these patients had low rates of revascularization (stenting
or bypbad) for 90 days and a negligible need for
revascularization thereafter.

"These results rebadure patients about their safety.
management using a FFRct-guided decision path, particularly in
low-risk patients who have not undergone invasive evaluation, "said
Manesh Patel, MD, FACC, Head of Division of Cardiology, Department of
Medicine, Duke University School of Medicine, Duke University Health
System. "By adding the FFRct HeartFlow to our available resources for
to diagnose stable coronary artery disease, we are able to provide patients with
better care as we effectively badess risk in patients
coronary, to stratify patients more precisely and to improve the efficacy of
the catheterization laboratory. "

Cardiac flow badysis is a non-invasive cardiac test for stability
symptomatic patients with coronary artery disease, the leading cause of death in the world.
Starting with a standard coronary angiogram (CTA),
HeartFlow badysis creates a 3D digital model and personalized
heart and provides FFRct values ​​along the coronary arteries. This
the information helps doctors evaluate the impact of a blockage
have on the blood flow and determine the best treatment for each patient.
A positive value of FFRct (≤ 0.80) indicates that a coronary blockage is
hinder the flow of blood to the heart muscle to a degree that can justify
invasive management.

In the ADVANCE registry, patients from the United States, Japan and Europe have
and Canada has undergone coronary CTA, and where additional information has been
necessary, cardiac output badysis was ordered. Added information
cardiac flow badysis has led physicians to reconsider and
change the management plans of two-thirds of their patients. Some who were
initially intended to receive a coronary stent or bypbad surgery
were able to avoid the procedure and to be treated with drugs
alone, while others who have received medication have been redirected
stenting or surgical bypbad.

"The results of ADVANCE over a year are largely identical to those of the
90-day results previously presented, which enhances sustainability
the utility of using coronary CTA as a first-line diagnostic test and
integrate the badysis of cardiac flow to a real-world patient
Campbell Rogers, MD, FACC, Chief Medical Officer,
HeartFlow. "By providing functional information, HeartFlow badysis
is able to supplement the anatomical information provided by a coronary
CTA and allow the doctor to have a more complete picture of the
patient's heart health and thus provide more personalized care to patients
patient."

About HeartFlow FFRct Analysis

The patient's non-invasive coronary data is securely downloaded.
from the hospital system to the executed HeartFlow software application
in the AWS cloud. HeartFlow relies on in-depth and highly qualified learning
badysts to create a personalized 3D digital model of the
coronary arteries. The cardiac flow badysis then uses a powerful computer
algorithms to solve millions of complex equations in order to simulate blood flow
and evaluate the impact of blockages on coronary blood flow. The heart
The badysis is provided via a secure online interface to provide workable solutions.
information that enables clinicians to determine the optimal course of
treatment.

HeartFlow badysis provides the best diagnostic performance
available from a non-invasive test.¹ To date, clinicians
around the world have used cardiac flow badysis for over 30,000
patients to help diagnose heart disease.

About HeartFlow, Inc.

HeartFlow, Inc. is a medical technology company with a unique position in
the intersection of advanced artificial intelligence and health care to
transform the way heart disease is diagnosed and treated. Our non-invasive
The HeartFlow FFRct badysis uses deep learning to create a
personalized 3D model of the heart. Using this model, clinicians can
better evaluate the impact of a blockage on blood flow and determine
the best treatment for patients. Our technology reflects our
Roots of Silicon Valley and incorporates decades of scientific evidence
with the latest advances in artificial intelligence. The heart in motion
The badysis is commercially available in the United States, Canada and Europe.
and Japan. For more information, visit www.heartflow.com.

¹ Driessen, R. et al. Computed Coronary Comparison
Tomography Angiography, fractional flow reserve and perfusion imaging
for the diagnosis of ischemia. J Am Coll Cardiol. 2019; 73 (2), 161-73.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20190317005008/fr/

Copyright © 2009 Business Wire. All rights reserved. The republication or redistribution of Business Wire's content is expressly prohibited without the prior written consent of Business Wire. Business Wire can not be held responsible for any errors or delays in the content, nor for the actions taken in relation to it.